Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Setmelanotide in Pseudohypoparathyroidism Type 1a (PHP1a) with Obesity
NCT07496463Phase 2Enrolling by invitation
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2026
- Primary completion
- Apr 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of setmelanotide in obesity, sponsored by Massachusetts General Hospital. Started Jul 2026; status: enrolling by invitation.
02
Drugs
setmelanotide
03
Conditions
obesity
Beyond the preview
Go deeper on NCT07496463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07496463.